CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.
Victoria Gray spent 34 years battling the debilitating pain of sickle cell disease. Then she volunteered to be the world's first "prototype" for a CRISPR therapy, based on technology invented at UC ...
Zacks Investment Research on MSN
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.
A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...
The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...
A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...
If I were to locate the moment AI slop broke through into popular consciousness, I’d pick the video of rabbits bouncing on a ...
If you are wondering whether CRISPR Therapeutics at about US$53.84 is still priced attractively or already baking in a lot of ...
Whales with a lot of money to spend have taken a noticeably bearish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades. If we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results